RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust

Revvity, Inc. RVTY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.42, which beat the Zacks Consensus Estimate of $1.36 by 4.4%. The bottom line improved 13.6% from the year-ago quarter’s level.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS from continuing operations was 78 cents compared with 64 cents in the prior-year period. However, GAAP EPS in the reported quarter was 78 cents, which includes an earnings of 5 cents per share from discontinued operations.Revenue DetailsBased in Waltham, MA, this leading MedTech company reported revenues of $729.3 million, up 4.8% year over year and 6% organically. The top line missed the Zacks Consensus Estimate by 0.1%.Segmental DetailsRevvity reports under two operating segments — Life Sciences and Diagnostics.Life SciencesRevenues from this segment totaled $336 million, indicating an increase of 5% from the year-ago quarter’s level, reportedly as well as organically.Adjusted operating income amounted to $131 million, up 11% from the prior-year quarter.DiagnosticsThis segment’s revenues totaled $393 million, up 4.5% on a year-over-year basis. Organically, the top line increased 6% year over year.Adjusted operating income amounted to $98 million, up 22.5% from the year-ago quarter’s figure.Revvity Inc. Price, Consensus and EPS Surprise Revvity Inc. price-consensus-eps-surprise-chart | Revvity Inc. QuoteMargin AnalysisSelling, general and administrative expenses totaled $244.3 million, down 4.8% year over year. Research and development expenses amounted to $49.2 million, down 0.8% from the year-ago quarter’s reported number.Adjusted operating income improved 15.4% to $221.3 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.3%, expanding 280 basis points.Financial UpdateThe company exited the fourth quarter of 2024 with cash and cash equivalents of $1.16 billion compared with $1.23 billion at the end of the prior quarter.Net cash provided by operating activities, including discontinued operations, totaled $174.2 million against net cash used in operating activities of $196.6 million in the year-ago quarter.2025 GuidanceRevvity issued its earnings and updated its revenue guidance for 2025.For 2025, the company expects its adjusted EPS to be in the range of $4.90-$5.00. Revenues are now anticipated to be in the band of $2.80-$2.85 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.97 and $2.87 billion, respectively.RVTY’s Zacks Rank & Stocks to ConsiderRVTY carries a Zacks Rank #4 (Sell) at present.Some better-ranked stocks in the broader medical space are Penumbra PEN, Masimo MASI and Inogen INGN.Penumbra, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 37.5% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.PEN’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%. The company is scheduled to release fourth-quarter results on Feb. 18.PEN’s shares have gained 42.8% compared with the industry’s 3.9% growth in the past six months.Masimo, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 11.8% for 2025.MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 58.5% compared with the industry’s 3.9% growth year to date. The company is scheduled to release fourth-quarter results on Feb. 25.Inogen, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 14.5% for 2025. It delivered a trailing four-quarter average earnings surprise of 12.40%. The company is scheduled to release fourth-quarter results on Feb. 25.INGN’s shares have risen 31.3% in the past six months compared with the industry’s 10.6% growth.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Revvity Inc. (RVTY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks